KKKamil Kuca

Kamil Kuca

*This is an algorithmically generated author record based on publicly available information.

Kamil Kuca has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Jun

    Department of Toxicology and Military Pharmacy Military Faculty of Medicine University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic

    8 shared publications
  • Jan Korabecny

    Department of Toxicology and Military Pharmacy Military Faculty of Medicine University of Defence in Brno Trebesska 1575 500 02 Hradec Kralove Czech Republic

    3 shared publications
  • Martina Hrabinova

    Department of Toxicology and Military Pharmacy Military Faculty of Medicine University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic

    3 shared publications
  • Filip Zemek

    Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 50005 Hradec Kralove, Czech Republic

    2 shared publications
  • Ilja Tachecí

    2nd Department of Medicine, Charles University in Praha, Faculty of Medicine at Hradec Králové, University Teaching Hospital, Sokolska 581, 500 05 Hradec Králové, Czech Republic

    2 shared publications
  • Jan Bures

    Department of Medicine, 1st Faculty of Medicine, Charles University, Military University Hospital Prague, U Vojenske Nemocnice 1200, 169 02 Prague, Czech Republic

    2 shared publications

Latest Publications

  • Open Access

    7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer’s Disease Treatment

    by Jan Korabecny, Martin Andrs, Eugenie Nepovimova, Rafael Dolezal, Katerina Babkova, Anna Horova, David Malinak, Eva Mezeiova, Lukas Gorecki, Vendula Sepsova, et al.

    Alzheimer’s disease (AD) is a debilitating progressive neurodegenerative disorder that ultimately leads to the patient’s death. Despite the fact that novel pharmacological approaches endeavoring to block the neurodegenerative process are still emerging, none of them have reached use in clinical practice yet. Thus, palliative treatment represented by acetylcholinesterase inhibitors (AChEIs) and memantine are still the only therapeutics used. Following the multi-target directed ligands (MTDLs) strategy, herein we describe the synthesis, biological evaluation and docking studies for novel 7-methoxytacrine-p-anisidine hybrids designed to purposely target both cholinesterases and the amyloid cascade. Indeed, the novel derivatives proved to be effective non-specific cholinesterase inhibitors showing non-competitive AChE inhibition patterns. This compounds’ behavior was confirmed in the subsequent molecular modeling studies.


  • Open Access

    Acetylcholinesterase inhibitors used or tested in Alzheimers disease therapy; their passive diffusion through blood brain barrier: In vitro study

    by Zdarova Karasova, Jana Zdarova Karasova, Jan Korabecny, Filip Zemek, Vendula Sepsova, Kamil Kuca

    Although the information about Alzheimer’s disease (AD) etiology is still unclear; acetylcholinesterase inhibitors still play a major role in symptomatic treatment of AD. Unfortunately, a relevant argumentation is complicated since information about real drug concentration in the brain or time-dependent blood-brain barrier (BBB) distribution studies are still quite rare. In this in vitro study, high-performance liquid chromatography (HPLC) method with special (IAM – immobilized artificial membrane) column was used to determine the ability of cholinesterase inhibitors to penetrate through BBB. Set of 8 structurally different cholinesterase inhibitors applicable to AD treatment was evaluated throughout this study. According to our method, all molecules are able to penetrate BBB by passive transport. However, some molecules such as huperzine A and galanthamine have lower ability to penetrate the BBB directly. These molecules may be delivered into the brain via active transport. Other molecules probably use passive transport to permeate into the central nervous system; tacrine and 7-methoxytacrine exert the highest passive permeation from this set of compounds. Key words: Blood-brain barrier, central nervous system, acetylcholinesterase, Alzheimer disease.


    • 1 January 2013
      • p. 74-8

    Intravenous application of HI-6 salts (dichloride and dimethansulphonate) in pigs: comparison with pharmacokinetics profile after intramuscular administration.

    by Jana Zdarova Karasova, Filip Zemek, Martin Kunes, Jaroslav Kvetina, Jaroslav Chladek, Daniel Jun, Jan Bures, Ilja Tachecí, Kamil Kuca

    Oxime HI-6 is an acetylcholinesterase reactivator therapeutically efficient against nerve agents. Because of their physico-chemical properties, oximes are typically applied intramuscularly (i.m.). This route of administration has also some disadvantages, and alternative strategies ought to be examined. We evaluated the pharmacokinetic profiles of two HI-6 salts after their intravenous (i.v.) administration, and compare the results with the known pharmacokinetics after i.m. administration. Pigs were administered with HI-6 salts (i.v), either HI-6 dichloride (10.71 mg/kg) or molar equivalent HI-6 dimethansulphonate (13.59 mg/kg). Doses of the HI-6 salts corresponded with a standard HI-6 dichloride dose in one autoinjector (500 mg) and were recalculated for one kilogram of body weight. The main pharmacokinetic parameters are comparable after i.v. and i.m. HI-6 administration. The compared pharmacokinetic parameters were half-life, terminal rate constant, mean residence time of the molecule in the body, clearance, and the apparent volume in the terminal phase. The bioavailability after i.m. administration was comparable with that of i.v.; these results suggest that the oxime is well released from the muscle depot. Significant differences were found in parameters Cmax and Tmax which are important in cases of emergency when rapidity and bioavailability are paramount for the success of treatment. I.v. administration should solve the problem of rapid clearance. Infusion or bolus administration may be considered as a logical subsequent step in oxime treatment strategy. The main advantage is in maintenance of an effective therapeutic plasma concentration, a more easily achievable effective therapeutic concentration, and fewer local adverse reactions.


    • 1 January 2013
      • p. 79-83

    Impact of paraoxon followed by acetylcholinesterase reactivator HI-6 on gastric myoelectric activity in experimental pigs.

    by Jan Bures, Jaroslav Kvetina, Michal Pavlik, Martin Kunes, Marcela Kopacova, Stanislav Rejchrt, Daniel Jun, Martina Hrabinova, Kamil Kuca, Ilja Tachecí

    Organophosphorus compounds represent nerve agents, pesticides and several industrial compounds. Treatment after exposure to organophosphates involves the use of parasympatolytics, acetylcholinesterase (AChE) reactivators/modulators and anticonvulsive drugs. Wider clinical use of several AChE reactivators/modulators might be limited because of possible side effects, including gastrointestinal toxicity. In this study we evaluated the effect of paraoxon and an AChE reactivator (HI-6) on the gastric myoelectric activity in experimental pigs. Six female experimental pigs (mean weight 33 kg) entered the study. Intramuscular paraoxon (1.5 g) was administrated after the baseline gastric electrogastrography (EGG) recording, followed by HI-6 dimethansulphonate (1.5 g i.m.) 10 min. later. A further ten 15-minute-interval EGG recordings were performed. Running spectral analysis was used for the elemental evaluation of the EGG. The results were expressed as dominant frequency of slow waves at all intervals of EGG recordings. EGG power analysis was performed in all animals. Paraoxon induced a non-significant decrease of dominant frequency (2.8±0.6 vs. 2.6±0.5 cycles per min.; p=0.092). Subsequent administration of HI-6 normalised dominant frequency to basal values and increased it significantly within the subsequent 30 minutes (3.0±0.4; p<0.001). Paraoxon administration did not influence the power (within a 10-minute exposure). However, the amplitudes increased significantly 90 minutes after administration of HI-6 (819±109 vs. 5054±732 μV2; p<0.001). AChE reactivator HI-6 blocked the gastric effect of paraoxon significantly. Subsequent myoelectric changes in the dominant frequency and power were executed by HI-6. The effect of paraoxon was non-significant.


    • 1 January 2011
      • Vol. 32  (3) , 259-63

    In vitro effects of acetylcholinesterase inhibitors and reactivators on Complex I of electron transport chain.

    by Jana Hroudová, Zdenĕk Fisar, Jan Korábečný, Kamil Kuča

    Inhibition of the enzyme acetylcholinesterase (AChE) is the main mechanism both of therapeutic action of drugs for the treatment of Alzheimer's disease and toxic action of organophosphorus compounds. Various types of oximes reactivate AChE and are commonly used as antidotes against organophosphates (pesticides, nerve agents). Effects both of AChE inhibitors (tacrine, 7-methoxytacrine) and oximes (pralidoxime, trimedoxime, obidoxime, methoxime, HI-6) on Complex I of electron transport chain (ETC) were examined. The enzyme activity was measured spectrophotometrically in crude mitochondrial fraction isolated from pig brain. Our results showed statistically significant Complex I inhibition by tacrine, other drugs did not affect the enzyme activity significantly. These observations suggest the possibility of tacrine-induced side effects related to disturbance in ETC. On the contrary, it seems that oximes do not affect cellular energetic metabolism.


  • Cholinesterase Reactivators as Prophylactics Against Nerve Agents

    by Jiri Bajgar, Kamil Kuca, Josef Fusek, Daniel Jun, Lucie Bartosova

    Prophylaxis against nerve agent intoxication is based on various approaches: Keeping AChE, key enzyme for toxic action of OP/nerve agents intact (protection of cholinesterases) is a basic requirement for effective prophylaxis. Detoxification realised by administration of the enzymes splitting the OP or evaluating specific enzymes (cholinesterases) is another possibility (scavenger effect). The antidotes currently used for the treatment of OP poisoning including reactivators are to be tested as prophylactics. This principle can be considered as a “treatment in advance”. Moreover, they are uneffective when administered alone; their effect is potentiated when they are administered with anticholinergics. Transdermal administration of reactivator HI-6 was used and prophylactic antidote TRANSANT was developed and introduced into the Czech Army. At present, PYRIDOSTIGMINE seems to be common prophylactic antidote; prophylactics PANPAL (tablets with pyridostigmine, trihexyphenidyle and benactyzine), TRANSANT (transdermal patch containing HI-6) are other means introduced into different armies as prophylactics. TRANSANT is only one prophylactics evaluating reactivator. When administered simultaneously with PANPAL, prophylactic efficacy is increased and represents the best prophylaxis at present.


  • Biosensors for nerve agents assay

    by Miroslav Pohanka, Daniel Jun, Kamil Kuca

  • Aflatoxin assay using an acetylcholinesterase based biosensor

    by Miroslav Pohanka, Daniel Jun, Kamil Kuca

    • 1 December 2006
      • Vol. 57  (4) , 387-90

    Substituted monoquaternary oximes as reactivators of cyclosarin--and chlorpyrifos--inhibited acetylcholinesterase.

    by Veronika Racakova, Martina Hrabinova, Daniel Jun, Kamil Kuca

    This paper describes an in vitro study of three potential acetylcholinesterase (AChE; EC 3.1.1.7) reactivators derived from a monoquaternary reactivator pralidoxime. Compounds used were pyridinium-2-aldoxime-4-carbamoyl-N-methyl iodide (TO231), pyridinium-2-aldoxime-4-ethoxycarbonyl-N-methyl iodide (TO237), and pyridinium-2-aldoxime-5-ethoxycarbonyl-N-methyl iodide (TO238). Pralidoxime and obidoxime were used for comparison. Nerve agent cyclosarin and pesticide chlorpyrifos were used as organophosphorus cholinesterase inhibitors. The source of AChE was rat brain homogenate. None of the tested oximes was able to reactivate cyclosarin-inhibited AChE (at 1.0 mmol L(-1) oxime concentration). In case of chlorpyrifos, TO231 was the most potent AChE reactivator with an 82 % reactivation at 1.0 mmol L(-1) oxime concentration. This reactivating potency equals that of pralidoxime and obidoxime. TO238 was less effective, and TO237 did not reactivate chlorpyrifos-inhibited AChE at all. None of the tested AChE reactivators, reference compounds included, could be considered universal for both chlorpyrifos- and cyclosarin-inhibited AChE.


    • 1 December 2006
      • Vol. 57  (4) , 391-5

    Equine butyrylcholinesterase protects rats against inhalation exposure to sublethal sarin concentrations.

    by Jiri Bajgar, Lucie Bartosova, Josef Fusek, Daniel Jun, Kamil Kuca

    Protection experiments were conducted using different doses of equine serum butyrylcholinesterase (Eq BuChE) as pretreatment in rats. Cholinesterase activities were determined in blood [whole blood, red blood cells (RBC) acetylcholinesterase (AChE), and plasma BuChE] before and after sarin inhalation exposure in untreated rats and those pretreated with Eq BuChE. Brain AChE activity was also determined in the frontal cortex, basal ganglia and pontomedullar areas following exposure. Dose-dependent increases in plasma BuChE activity and no changes in the RBC and brain AChE activities were demonstrated following i.p. injection of different amounts of Eq BuChE. Decreases in plasma BuChE activity and RBC and brain AChE activities were observed in control rats following sarin inhalation exposure. In rats pretreated with Eq BuChE this inhibition was lower than in control animals. These results demonstrate protective effects of Eq BuChE pretreatment in rats intoxicated with sublethal concentrations of sarin by inhalation.